fig2
![Is it time to introduce anti-inflammatory drugs into secondary cardiovascular prevention: evidence from clinical trials?](https://image.oaes.cc/0f515c1e-6a9c-4191-aa4d-dec70b610ef4/3942.fig.2.jpg)
Figure 2. Secondary prevention strategies for patients with documented chronic coronary syndromes. Anti-inflammatory therapy will likely be included in future guidelines. ACE: Angiotensin converting enzyme; ARB: angiotensin II receptor blocker; ASA: aspirin; EF: ejection fraction; GLP1 RA: glucagon-like peptide-1 receptor agonist; Hb: hemoglobin; HFP: heart failure; i: inhibitor; LDL: low density lipoprotein; LVD: left ventricular dysfunction; PCSK9: proprotein convertase subtilisin/kexin type 9; SBP: systolic blood pressure; SGLT2: sodium-glucose cotransporter-2.